World Library  
Flag as Inappropriate
Email this Article

Indinavir

Article Id: WHEBN0003779420
Reproduction Date:

Title: Indinavir  
Author: World Heritage Encyclopedia
Language: English
Subject: Discovery and development of HIV-protease inhibitors, Protease inhibitor (pharmacology), Management of HIV/AIDS, Didanosine, Kidney stone
Collection:
Publisher: World Heritage Encyclopedia
Publication
Date:
 

Indinavir

Indinavir
Systematic (IUPAC) name
(2S)-1-[(2S,4R)-4-benzyl-2-hydroxy-4-{[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]carbamoyl}butyl]-N-tert-butyl-4-(pyridin-3-ylmethyl)piperazine-2-carboxamide
Clinical data
Trade names Crixivan
AHFS/Drugs.com
MedlinePlus
Licence data US FDA:
Pregnancy
category
  • US: C (Risk not ruled out)
Routes of
administration
Oral
Pharmacokinetic data
Bioavailability ~65%
Protein binding 60%
Metabolism Hepatic via CYP3A4
Biological half-life 1.8 (± 0.4) hours
Identifiers
CAS Registry Number  Y
ATC code J05
PubChem CID:
DrugBank  Y
ChemSpider  Y
UNII  Y
KEGG  Y
ChEBI  Y
ChEMBL  N
NIAID ChemDB
PDB ligand ID MK1 (, )
Chemical data
Formula C36H47N5O4
Molecular mass 613.79 g/mol
 N   

Indinavir (IDV; trade name Crixivan, manufactured by Merck) is a protease inhibitor used as a component of highly active antiretroviral therapy to treat HIV/AIDS.

HIV-1 protease in complex with indinavir. PDB entry [1]

It is on the health system.[2]

Contents

  • Medical uses 1
  • Side effects 2
  • History 3
  • Synthesis 4
  • References 5

Medical uses

Unfortunately, indinavir wears off quickly after dosing, so requires very precise dosing every eight hours to thwart HIV from forming drug-resistant mutations, including resistances to other protease inhibitors. It has restrictions on what sorts of food may be eaten concurrently. For these reasons it is now rarely used.

Side effects

The most common side effects of indinavir include:[3]

Indinavir inhibits urinary nitrous oxide production and may inhibit nitric oxide production. Treatment with this drug is frequently associated with renal abnormalities, sterile leukocyturia, and reduced creatinine clearance.[4]

Indinavir impairs endothelial function in healthy HIV-negative men and may accelerate atherosclerotic disease.[5]

History

The Food and Drug Administration approved indinavir on March 13, 1996, making it the eighth approved antiretroviral. Indinavir is much more powerful than any prior antiretroviral drug; using it with dual NRTIs set the standard for treatment of HIV/AIDS and raised the bar on design and introduction of subsequent antiretroviral drugs. Protease inhibitors changed the very nature of the AIDS epidemic from one of a terminal illness to a somewhat manageable one.

Increasingly, it is being replaced by newer drugs that are more convenient to take and less likely to promote virus resistance, such as darunavir or atazanavir.

Synthesis

Indinavir synthesis:[6]

References

  1. ^ Liu, F.; Boross, P. I.; Wang, Y. F.; Tozser, J.; Louis, J. M.; Harrison, R. W.; Weber, I. T. (2005). "Kinetic, Stability, and Structural Changes in High-resolution Crystal Structures of HIV-1 Protease with Drug-resistant Mutations L24I, I50V, and G73S". Journal of Molecular Biology 354 (4): 789–800.  
  2. ^ "WHO Model List of EssentialMedicines" (PDF). World Health Organization. October 2013. Retrieved 22 April 2014. 
  3. ^ (indinavir sulfate) Capsules. Prescribing Information. Revised December 2013"®"Crixivan (PDF). Merck & Co., Inc. Retrieved 6 February 2014. 
  4. ^ M. Eira, M. Araujo and A.C. Seguro. excretion and renal failure in indinavir-treated patients3Urinary NO. Brazilian Journal of Medical and Biological Research (2006) 39: 1065-1070.
  5. ^ Shankar SS, Dubé MP, Gorski JC, Klaunig JE, Steinberg HO. Indinavir impairs endothelial function in healthy HIV-negative men. Am Heart J. 2005 Nov;150(5):933.
  6. ^ Askin, D.; Eng, K. K.; Rossen, K.; Purick, R. M.; Wells, K. M.; Volante, R. P.; Reider, P. J. (1994). "Highly diastereoselective reaction of a chiral, non-racemic amide enolate with (S)-glycidyl tosylate. Synthesis of the orally active HIV-1 protease inhibitor L-735,524". Tetrahedron Letters 35 (5): 673.  
This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and USA.gov, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for USA.gov and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
 
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
 
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.
 



Copyright © World Library Foundation. All rights reserved. eBooks from World eBook Library are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.